NICE issues Appraisal Consultation Document on pegloticase for severe gout

Source: NICE Area: News The National Institute for Health and Clinical Excellence (NICE) has issued for consultation, an Appraisal Consultation Document (ACD) on pegloticase for the treatment of severe gout.   The following preliminary recommendations have been made:   . Pegloticase is not recommended within its marketing authorisation, that is, for treating severe debilitating chronic tophaceous gout in adults who may also have erosive joint involvement and in whom xanthine oxidase inhibitors at the maximum medically appropriate dose have failed to normalise serum uric acid or for whom these medicines are contraindicated.   . People currently receiving pegloticase for severe gout should be able to continue treatment until they and their clinician consider it appropriate to stop.   The consultation period closes on 22 February 2013
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news